Visiongain has published a new report entitled Biologics Market Report 2025-2035

The biologics market is estimated at US$498.1 billion in 2025 and is projected to grow at a CAGR of 8.5% during the forecast period 2025-2035.

Rising Geriatric Population Propelling Market Growth

By 2030, the WHO estimates that nearly one in six people worldwide will be 60 years or older. Currently, the global population aged 65 and above stands at approximately 830 million, a figure expected to rise to 1.7 billion by 2054, according to the latest UN projections. Additionally, the number of individuals aged 80 and older is set to triple between 2022 and 2050, reaching around 426 million. The United Nations predicts that the global elderly population will nearly double by 2050. This demographic shift presents a substantial market opportunity for biologics designed to support older adults in maintaining independence, enhancing mobility, and improving overall well-being.

What are the Current Market Drivers?

Continuous Research and Development Boosting Market Growth 

Continuous research and development are expanding the scope of conditions that biologics can treat, driving demand as new indications and therapeutic possibilities emerge. Advances in biotechnology, including genetic engineering and cell therapy, are accelerating the development of innovative biologics, further expanding the market. Notable examples include Herceptin (Trastuzumab) by Genentech, which has transformed HER2-positive breast cancer treatment, and Avastin (Bevacizumab), also by Genentech, which is widely used for colorectal and other cancers.

Developing Economies Projected to Spur Industry Growth

Key developing economies such as Brazil, Russia, India, China, South Africa, Mexico, South Korea, Indonesia, and Turkey are witnessing rapid pharmaceutical market expansion, collectively accounting for a 20% share of the global biologics market. This growth is driven by large populations, rising incomes, and increasing life expectancy, while mature markets grapple with challenges like patent expirations and stringent regulations. Singapore, a leading biopharmaceutical hub, has attracted global players like GlaxoSmithKline and Novartis through its strong research ecosystem. The country’s thriving biotech sector, contributing about 5% to its GDP, hosts over 350 companies, including major players such as RVAC Medicines and Tessa Therapeutics.

Where are the Market Opportunities?

Increasing Importance of Genomics and Proteomics  

The growing significance of genomics and proteomics is a key driver of the biologics market, as these disciplines are instrumental in the discovery, development, and production of biologic therapies. By identifying and validating molecular targets in disease pathways, genomics and proteomics research enables the development of biologics tailored to specific conditions.

These fields help pinpoint biomarkers associated with diseases, aiding in patient stratification, early diagnosis, and the monitoring of biologics’ efficacy in clinical trials. Insights from genomics and proteomics accelerate drug discovery, enabling the design of biologics such as monoclonal antibodies that precisely target proteins or nucleic acids.

Competitive Landscape

The biologics market is characterized by a high degree of fragmentation, featuring numerous companies and products. In 2025, key players such as Pfizer Inc., AbbVie Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Gilead Sciences, Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Sanofi, Regeneron Pharmaceuticals, Inc., Eli Lilly and Company, GSK plc, Novo Nordisk A/S, Amgen Inc., Biogen Inc., and Celltrion, Inc. are expected to collectively hold the majority market share. These major players have implemented various strategies, including mergers and acquisitions, substantial investments in research and development, collaborative initiatives, partnerships, regional business expansion, and the introduction of innovative products to enhance their positions in the market.

Some Recent Developments

• On 23^rd January 2025, AbbVie completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.
• On 9^th January 2025, Johnson & Johnson announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S. Food and Drug Administration (FDA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) patients with generalized myasthenia gravis (gMG), as supported by findings from the Phase 3 Vivacity-MG3 study.

How will Visiongain’s Biologics Market Report 2025-2035 Report Benefit you?

Visiongain’s 367-page report provides 136 tables and 228 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the biologics market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Biologics. Get financial analysis of the overall market and different segments including scale of operation, size of contract manufacturer, and source of stem cells, type of stem cells, and end-user and capture higher market share. We believe that there are strong opportunities in this fast-growing biologics market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What Content is Included?

Forecasts by Product (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Regenerative Medicine, Others), by Application (Oncology, Infectious Diseases, Autoimmune Disease, Haematological Disorder, Cardiovascular Disorders, Others), by Manufacturing Type (Outsource, In-house), by Source (Mammalian, Mircobial, Others), by End-users (Hospitals, Speciality Centres, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.